Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

NOVATO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical significance observed between the 6R-BH4 treatment and placebo groups.

The primary endpoint of the study, peak walking time (PWT), did not show a significant difference between 6R-BH4 and placebo, and the secondary endpoint, claudication onset time, also did not show a difference. Addition of Vitamin C to 6R-BH4 did not improve efficacy on PWT. Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did not show a significant benefit with 6R-BH4. Urinary protein excretion did not decrease with 6R-BH4 treatment, though there may have been some effect in the subset of patients with microalbuminuria at baseline. 6R-BH4 was well-tolerated in peripheral arterial disease patients and had a safety profile similar to previous studies.

Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated, "We are disappointed that the results of 6R-BH4 in peripheral arterial disease were not statistically significant. We have upcoming data in several BioMarin and investigator-sponsored studies of 6R-BH4 including proteinuria, pulmonary arterial hypertension and 6R-BH4 plus Vitamin C in patients with endothelial dysfunction. Along with the prior results in sickle cell disease, these data will determine the future of the 6R-BH4 cardiovascular program once all the studies are complete."

Study Design

The Phase 2 multi-center, randomized, double-blind, placebo-controlled study enrolled 190 subjects and was conducted at 31 sites in the U.S. and Argentina. 161 patients comple
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/28/2014)... July 28, 2014 Sapphire Energy, Inc. ... announced the appointment of biotechnology veteran James Levine ... of directors. Levine replaces Cynthia ,CJ, Warner, who is ... remain chairman of the company,s board of directors. ... mission to deliver commercial scale algae-based fuels has been ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... like when it was a baby. They know what it ... looked in its youth. Thanks to technological advances, however, scientists ... of how the cosmos developed into the kind of place ... They plan to gather these never-before-obtained insights with a potentially ...
... BOTHELL, Wash., June 30, 2011 SCOLR Pharma, Inc. ... second and final tranche of its previously-announced private placement ... (the "Debentures").  The Company raised a total of $1,190,200 ... net proceeds for working capital and other general corporate ...
... OXIS International, Inc. (OTC Bulletin Board: OXIS ; ... Saloff to its Board of Directors.  The Company,s Board now ... are very pleased to have David Saloff, an outstanding businessmen ... said Anthony J. Cataldo, Chairman of OXIS International. "OXIS is ...
Cached Biology Technology:Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4SCOLR Pharma, Inc. Announces Final Closing of Private Placement 2SCOLR Pharma, Inc. Announces Final Closing of Private Placement 3OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 2OXIS International Names Healthcare Industry Entrepreneur David Saloff to Board of Directors 3
(Date:7/28/2014)... 100 drugs already approved by the U.S. Food and ... the growth of certain bacterial pathogens inside human cells, ... spotted fever. The findings, published in mBio , ... Microbiology, demonstrate a new way of identifying non-antibiotic drugs ... , A handful of drugs on the list inhibit ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
(Date:7/28/2014)... in the United States have a circulatory problem of ... painful and may even require surgery in serious cases. ... and, in turn, limb amputation. , At The University ... School, scientists tested a non-surgical preventative treatment in a ... with increased blood circulation. Their proof-of-concept study appears ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... American Academy of Pediatrics National Children,s Art Contest drew hundreds ... With the theme of "My Healthy Lifestyle," the 2011 ... obesity, diet, exercise, sleep and limiting screen time. This was ... of the three age groups each receive a $500 cash ...
... grown apple may hold within it a tiny bit of ... teamed up on a startup that promises to turn slash ... for farmers that helps their soil hold water and nutrients. ... for farmers. "Wine growers, organic farmers and gardeners of all ...
... generally considered to be a good thing for people ... too risky for women who are also pregnant. Some ... the risk of women developing preeclampsia, a condition that ... this might happen has remained unknown. New research using ...
Cached Biology News:Turning slash piles into soil benefit 2Exercise before and during early pregnancy increases two beneficial proteins for mothers-to-be 2